Reuters: Money lined up for Watson to buy Actavis

No deal has been announced, but the money may already be lined up. That is the contention of Reuters, which earlier this week cited sources as saying Watson Pharmaceuticals ($WPI) has Actavis in its sights. Today, the news service says banks are falling all over themselves to provide financing for said deal, according to sources. It could take $6 billion to combine the two generics manufacturers, and that certainly would be a significant transaction. Bank of America Merrill Lynch, which has a relationship with Watson, is the front-runner to lead a deal that will probably involve a $2 billion term loan and a $4 billion bridge-to-bond arrangement, the news service says. Story | More